Interview with Tomáš Matějovský, Partner, CMS Cameron McKenna Czech…
Mr. Matějovský, let’s begin our discussion with a very simple question. The Czech Republic is quite a small country, and yet it seems to have one of the most complicated…
Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world’s leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.
In the Czech Republic, Sanofi Genzyme focuses on the diagnosis and treatment of rare diseases, respectively, lysosomal storage diseases, and multiple sclerosis (MS).
Contact
Sanofi Genzyme Czech Republic
Evropská 846/176A
160 00 Prague 6, Czech Republic
Tel: +420 233 086 111
Fax: +420 233 086 222
Mr. Matějovský, let’s begin our discussion with a very simple question. The Czech Republic is quite a small country, and yet it seems to have one of the most complicated…
Today, the Czech Republic is widely recognized as a major regional hub for clinical development. How would you compare the current environment to the realities of 1992, when CEPHA was…
You joined this affiliate in October of 2011, having spent the preceding three years as GM for Servier Slovakia. What are the principal differences you found between these two markets?…
Dr. Novotný, in 2008, you became Managing Director for MSD for the Czech and Slovak Republics. In the very next year after your appointment, you were tasked with managing the…
Dr. Heger, you were appointed as the Czech Minister of Health in July of 2010. What challenges did you see for the Czech healthcare system, and what has been your…
Mr. Krýza, Mr. Nádvorník, between the two of you, you have over 21 years of experience at Cegedim, and have watched this company grow significantly through a series of mergers.…
Mr. Krýza, Mr. Nádvorník, between the two of you, you have over 21 years of experience at Cegedim, and have watched this company grow significantly through a series of mergers.…
Ms. Hauser, you represent what is perhaps the last major generation of medical doctors in this country that left the medical field to join the pharmaceutical business. What do you…
Mr. Krejčí, can you please begin with a broad introduction to Ewopharma, for those of our readers who are unfamiliar with the company? Ewopharma is part of a large group…
Mr. Zahradnik, you have long been an active member of the Czech generic drug makers’ association CAFF (Czech Association of Pharmaceutical Firms), chairing the organization. Dr. Zörner, executive director of…
Mr. Polach, can you please begin with an introduction to CzechBio and explicate the association’s mission on this market? CzechBio is an association of Czech biotech companies that started its…
Mr. Chadim, after Astellas was formed from the merger between Yamanouchi and Fujisawa, it became your job to lead its Czech subsidiary. Tapani Sura, your colleague at Astellas Poland, has…
See our Cookie Privacy Policy Here
